Abstract: The present invention relates to a composition comprising cannabidiol and at least two excipients, wherein at least one excipient is a lipid excipient and wherein at least one excipient is a hydrophilic excipient, and wherein the lipid excipient is present in an amount equal to or lower than 20% of the total weight of the composition; the invention also relates to the preparation process of the composition and to pharmaceutical or nutraceutical formulations containing it.

Abstract: Disclosed are compositions including berberine combined with pea proteins and one or more surfactants. Also disclosed are processes for the preparation of the compositions, and the formulations and uses thereof.

Abstract: The invention relates to a process for the preparation of Melphalan (4-[bis(2-5 chloroethyl)amino]-L-phenylalanine of formula (I) said process comprising the reaction of a 4-amino-L-phenylalanine protected at the carboxy and amino aminoacidic groups with an agent able to convert the aromatic amino group into a group of formula: —N(CH2CH2OS(O)nO—)2, wherein n is 1 or 2 followed by conversion of the ?N(CH2CH2OS(O)nO—)2 group into a —N(CH2CH2Cl)2 group. The invention also provides novel intermediates useful for the preparation of Melphalan.

Abstract: The invention relates to a process for the preparation of Melphalan (4-[bis(2-chloroethyl)amino]-L-phenylalanine of formula (I) said process comprising the reaction of a 4-amino-L-phenylalanine protected at the carboxy and amino aminoacidic groups with an agent able to convert the aromatic amino group into a group of formula: —N(CH2CH2OS(O)nO?)2, wherein n is 1 or 2 followed by conversion of the —N(CH2CH2OS(O)nO?)2 group into a —N(CH2CH2Cl)2 group. The invention also provides novel intermediates useful for the preparation of Melphalan.

Abstract: Disclosed are powder solid compositions including a hydroalcoholic extract of Bergamot fruit (Citrus aurantium var. bergamia) and at least one phospholipid. Also disclosed is a process for the preparation of the compositions. The compositions are useful for the prevention and/or treatment of dysmetabolic syndromes, dyslipidemias and type 2 diabetes.

Abstract: The invention relates to a process for the preparation of colchicine 1 from colchicoside 2 which comprises enzymatic conversion of colchicoside 2 to 3-O-demethylcolchicine 3, wherein the enzyme used is a cellulase. According to another aspect of the invention, 3-O-demethylcolchicine 3 can be converted to colchicine 1 using an alkylating agent. The invention also relates to a process or enriching the colchicine 1 content of extracts from plants belonging to the Colchicaceae family containing colchicine 1, colchicoside 2 and 3-(9-demethyl colchicine 3, which comprises conversion by means of a colchicoside 2 cellulase to 3-O-demethylcolchicine 3, followed by conversion of 3-O-demethylcolchicine 3 to colchicine 1 using an alkylating agent.

Abstract: Disclosed is a process for the purification of staurosporine (1), which comprises salification of staurosporine (1) (Formula (1)) by treatment with a mineral acid to give a precipitated salt, isolation of the staurosporine (1) precipitated salt, treatment of the staurosporine (1) isolated salt with an organic base, and isolation of staurosporine (1). Also disclosed are novel polymorphic forms of the mono- and bis-hydrochloride salts of staurosporine (1).

Abstract: The invention relates to a process for the preparation of Melphalan (4-[bis(2-5 chloroethyl)amino]-L-phenylalanine of formula (I) said process comprising the reaction of a 4-amino-L-phenylalanine protected at the carboxy and amino aminoacidic groups with an agent able to convert the aromatic amino group into a group of formula: —N(CH2CH2OS(O)nO—)2, wherein n is 1 or 2 followed by conversion of the ?N(CH2CH2OS(O)nO—)2 group into a —N(CH2CH2Cl)2 group. The invention also provides novel intermediates useful for the preparation of Melphalan.

Abstract: Disclosed are compositions comprising grape seed extracts, in particular extracts with a proanthocyanidin content exceeding 95% by weight and a catechin and epicatechin content ?5% and ?15% by weight, which are useful to prevent or reduce the perception of stress symptoms, in particular the perception of stress among the male population.

Abstract: Disclosed are compositions comprising: a) an extract of Curcuma longa, curcumin or phospholipid-complexed curcumin; b) a lipophilic extract of Zingiber officinale; and c) a lipophilic extract obtained from plants containing isobutylamides of polyunsaturated fatty acids selected from the group consisting of Echinacea spp. extract, Zanthoxylum spp. extract and Acmella oleracea (Spilanthes oleracea) extract.

Abstract: The present invention relates to solid dispersions comprising a salt of ursolic acid with an alkali metal and a phospholipid and to oral dosage formulations containing them. The invention also relates to processes for preparing the solid dispersions and to the use of the solid dispersions and formulations for the prevention and/or treatment of a variety of pathological conditions in which hepatoprotective, antioxidant, anti-inflammatory, antiviral and cytotoxic activities are desired.

Abstract: The invention discloses a process for the preparation of maytansinoid esters of formula (I) comprising a thiol or disulphide group wherein R1, R4 and R5 and the asterisk are as defined in the description, by reacting maytansinol with an enantiopure alpha-azido acid, followed by reduction of the azido group and reacting the obtained amino-ester with a compound of formula (IX) (IX) R3—S—S—X—COOH wherein X and R3 are as defined in the description, or with a reactive derivative thereof and optionally reducing the obtained disulfide-containing maytansinoid ester to give a maytansinoid ester wherein R1 is a —X—SH group.

Abstract: The invention relates to compositions in the form of solid dispersions, comprising: a) curcumin or an extract containing it; b) coenzyme Q10; c) a phospholipid, and d) a pharmaceutically or nutraceutically acceptable carrier. The invention also relates to a process for the preparation of the compositions and the use of the compositions to prepare pharmaceutical or nutraceutical formulations for use in enhancing energy metabolism and the cognitive functions and improving the cardiovascular function and the quality of aging.

Abstract: Disclosed are powder solid dispersions including quercetin, phospholipids and a very to freely water soluble carrier. Also disclosed are a process for the preparation of the powder solid dispersions and pharmaceutical, nutraceutical and cosmetic compositions including the solid dispersions.

Abstract: The invention discloses a process for the preparation of maytansinoid esters of formula (I) comprising a thiol or disulphide group wherein R1, R4 and R5 and the asterisk are as defined in the description, by reacting maytansinol with an enantiopure alpha-azido acid, followed by reduction of the azido group and reacting the obtained amino-ester with a compound of formula (IX) (IX) R3—S—S—X—COOH wherein X and R3 are as defined in the description, or with a reactive derivative thereof and optionally reducing the obtained disulfide-containing maytansinoid ester to give a maytansinoid ester wherein R1 is a —X—SH group.

Abstract: Extract obtainable by extraction from Phaseolus sp. with mixtures of ethanol and water, characterised by an ?-amylase inhibitor content in between 1,000 and 1,600 USP/mg (HPLC titre between 6 and 14% w/w) and a phytohaemagglutinin content in between 8,000 and 30,000 HAU/g, and a process for its preparation.

Abstract: A process for the synthesis of Cannabidiol of formula (1): (1) is herein disclosed. The process comprises contacting a solution [solution (S1)] of (+)-p-mentha-diene-3-ol of formula (4) (4) or an ester thereof and olivetol of formula (3): (3) with a solution [solution (S2)] of a non-supported Lewis acid in a continuous flow reactor and treatment of the resulting mixture with a basic solution. The process offers the advantage that it can be conveniently carried out on an industrial scale while avoiding the formation of abnormal CBD and THC (?9-tetrahydrocannabinol).

Abstract: The present invention relates to a process for the preparation of Lenvatinib of formula (I) from 4-amino-3-chloro-phenol and 4-chloro-7-methoxyquinoline-6-carboxamide.

Abstract: Disclosed is a process for the preparation of powder compositions including a lipophilic extract of Echinacea spp., a lipophilic extract of Zingiber officinale and phospholipids. Also disclosed are powder compositions obtainable by the process and pharmaceutical, nutraceutical and cosmetic formulations including the compositions. Also described is a use of the powder compositions and formulations thereof in the prevention and/or treatment of inflammatory and painful states.

Abstract: The present invention relates to compositions comprising an American cranberry extract combined with phospholipids, and the use thereof in the prevention and treatment of urinary tract infections. The invention also relates to processes for the preparation of said compositions, and formulations for oral administration comprising said compositions.